Form 4: Madrigal Pharmaceuticals CMO Executes Tax-Related Stock Sale

Chief Medical Officer David Soergel sold 844 shares of Madrigal Pharmaceuticals to satisfy tax obligations related to RSU vesting.

Summary

• David Soergel, Chief Medical Officer of Madrigal Pharmaceuticals, sold 844 shares of common stock on May 18, 2026.
• The shares were sold at a price of $515.90 per share.
• The transaction was executed automatically to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• Following this transaction, the reporting person retains beneficial ownership of 11,075 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a routine administrative action related to tax obligations rather than a discretionary market move.

Positives

• The sale was non-discretionary and strictly for tax compliance purposes, indicating no change in the executive's long-term outlook on the company.

Negatives

• Reduction in the direct equity stake held by a key member of the executive leadership team.

Risks

• General market volatility affecting the valuation of pharmaceutical equity holdings.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this regulatory filing.

Management Comments

• The filing notes that the sale was automatic and not at the discretion of the Reporting Person.

Industry Context

StockSavvy.ai notes that automatic sell-to-cover transactions are standard practice in the biotechnology sector for executives to manage tax liabilities arising from equity-based compensation vesting.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive equity management.
• The use of Rule 10b5-1 style automatic sales is consistent with industry norms for mitigating insider trading concerns.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a pre-planned tax-related event.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Madrigal Pharmaceuticals, MDGL, Insider Trading, Form 4, Biotech, Executive Compensation